A mongolian medicine featured enema for treating ulcerative colitis

Abstract

The application discloses a Mongolian medicine characteristic enema for treating ulcerative colitis and relates to the technical field of biological medicine. The enema is prepared from a Mongolian medicine composition. The Mongolian medicine composition comprises the following components in parts by weight: Punica granatum 25-35 parts, Cinnamomum cassia 15-25 parts, cold water stone 15-25 parts, Amomum villosum 15-25 parts, Forsythia suspense 15-25 parts, Curcuma longa 15-25 parts, Terminalia chebula 15-25 parts, dried ginger 15-25 parts, Calvatia 15-25 parts, Caulis Sargentodoxae 15-25 parts, Radix Glycyrrhizae 5-15 parts, Platycladus orientalis 5-15 parts, Amomum kravanh 5-15 parts, alkali 5-15 parts and Polygonatum 5-15 parts. The Mongolian medicine characteristic enema has the advantages of improving the local effect of the medicine, reducing adverse reactions, having clear clinical curative effect and being innovative in the Mongolian medicine characteristics, and can provide a safe, effective and economical treatment scheme for UC patients.

Description

Technical Field

[0001] This invention relates to the field of biomedical technology, and in particular to a Mongolian medicine-specific enema for treating ulcerative colitis. Background Technology

[0002] Data shows that about one-quarter of colorectal cancer patients have an etiology and pathogenesis related to chronic inflammation, namely colitis-associated colon cancer (UCACC), with a mortality rate as high as 15%. Before the onset of UCACC, there is at least a precancerous evolution period of several decades. Therefore, effective treatment of chronic nonspecific ulcerative colitis (UC) is crucial for the prevention and treatment of UCACC and has practical significance.

[0003] Western medicine offers a wide variety of methods for preventing and treating chronic ulcerative colitis (UCACC), with new drugs and methods constantly emerging. However, regardless of the approach used, long-term survival rates and quality of life for patients remain unsatisfactory. Currently, many scholars are attempting to find drugs that can prevent UCACC while treating UC, hoping these drugs can reverse, inhibit, and prevent the occurrence and development of UCACC. Mongolian medicine, characterized by its multi-system, multi-link, and multi-target regulation, exhibits significant efficacy, low relapse rate, and relatively few toxic side effects, giving it unique advantages in the prevention and treatment of chronic diseases. In recent years, an increasing number of experimental studies have affirmed the role of traditional Chinese medicine in the prevention and treatment of UCACC.

[0004] Ulcers (UC) are a disease characterized by abdominal pain, diarrhea, bloody and mucous stools, and tenesmus, often accompanied by damage to multiple extraintestinal organs. Due to its recurrent and persistent nature, UC severely impacts patients' quality of life. Western medicine often employs aminosalicylic acid preparations, glucocorticoids, azathioprine analogs, and biological agents for treatment. However, these treatments suffer from drawbacks such as long treatment duration, lack of specificity, poor efficacy, high incidence of adverse reactions, poor patient tolerance, and compromised treatment adherence.

[0005] UC (ulcerative colitis) is a Mongolian medical condition known as "large intestine baoru disease." Ancient Mongolian medical texts state that "if large intestine baoru is a chronic condition that does not heal, it can lead to stagnation and accumulation of masses under the influence of the pathogenic factor 'heyi,' often resulting in blood stasis." Historically, Mongolian medicine has followed the treatment principle of suppressing the pathogenic factor and regulating the three roots (often referred to as "three roots"), using Mongolian medicine in conjunction with external therapies to treat this disease with proven efficacy and relatively fewer side effects. Intestinal administration is particularly unique and advantageous.

[0006] Currently, with in-depth research into the physiological functions of the large intestine, the use of medication via the anal and rectal route has gradually attracted the attention of researchers, and its scientific validity and good efficacy have been recognized. For ulcerative colitis (UC), local enema administration allows the drug to directly reach the affected area, resulting in high drug absorption and utilization rates, fewer adverse reactions, and definite clinical efficacy, significantly superior to oral medication treatment. Based on this, this invention aims to develop a Mongolian medicine-specific enema for the treatment of ulcerative colitis, achieving effective treatment for this condition. Summary of the Invention

[0007] The purpose of this invention is to provide a Mongolian medicine-specific enema for treating ulcerative colitis, thereby addressing the problems existing in the prior art. This Mongolian medicine-specific enema has significant technical advantages in treating ulcerative colitis.

[0008] To achieve the above objectives, the present invention provides the following solution:

[0009] This invention provides a Mongolian medicine composition for treating ulcerative colitis, comprising the following components in parts by weight:

[0010] 25-35 parts pomegranate seeds, 15-25 parts cinnamon, 15-25 parts gypsum, 15-25 parts cardamom, 15-25 parts forsythia, 15-25 parts turmeric, 15-25 parts chebula, 15-25 parts dried ginger, 15-25 parts puffball, 15-25 parts akebia stem, 5-15 parts prepared licorice root, 5-15 parts arborvitae, 5-15 parts long pepper, 5-15 parts alkali, and 5-15 parts polygonatum.

[0011] Preferably, the Mongolian medicine composition comprises the following components in parts by weight: 30 parts pomegranate seeds, 20 parts cinnamon, 20 parts gypsum, 20 parts cardamom, 20 parts forsythia, 20 parts turmeric, 20 parts chebula, 20 parts dried ginger, 20 parts puffball, 20 parts akebia stem, 10 parts prepared licorice root, 10 parts arborvitae, 10 parts long pepper, 10 parts alkali, and 10 parts polygonatum.

[0012] The present invention also provides the use of the above-mentioned Mongolian medicine composition in the preparation of a medicament for treating ulcerative colitis.

[0013] Furthermore, the drug is in the form of a powder or an enema.

[0014] The present invention also provides a medicine for treating ulcerative colitis, the raw materials of which include the above-mentioned Mongolian medicine composition.

[0015] Furthermore, the drug also includes pharmaceutically acceptable excipients.

[0016] Furthermore, the drug is in powder form.

[0017] Furthermore, the drug is an enema.

[0018] The present invention also provides a method for preparing the above-mentioned powder, comprising the step of uniformly mixing the medicinal powders of each component in the above-mentioned Mongolian medicine composition in the prescribed amount to obtain the powder.

[0019] The present invention also provides a method for preparing the above-mentioned enema agent, comprising the following steps;

[0020] Mix the medicinal powders of each component in the above-mentioned Mongolian medicine composition evenly to obtain a mixture;

[0021] The mixture is added to distilled water and boiled. After cooling, the insoluble matter is separated and removed to obtain a clear liquid, which is the enema agent.

[0022] Pomegranate seeds are sour and sweet in taste and neutral in nature. They have the effects of stopping diarrhea, astringing and stopping bleeding, and calming the nerves. They are used for chronic diarrhea, indigestion, hematochezia and other symptoms.

[0023] Cinnamon has a pungent and sweet taste and is warm in nature. It has the effects of dispelling cold and relieving pain, and promoting blood circulation. It is used for symptoms such as palpitations, chest tightness and shortness of breath.

[0024] Cold water stone is salty and warm in nature; it has the effects of detoxification and aiding digestion, and is used for indigestion, stomach bloating and pain, etc.

[0025] Cardamom has a pungent taste and warm properties; it has the effects of warming the kidneys and promoting diuresis, and is used for symptoms such as fatigue, stagnation of qi in the spleen and stomach, and diarrhea.

[0026] Forsythia has a bitter taste and slightly cold properties; it has the effects of clearing heat and detoxifying, reducing swelling, and relieving sores. It is used for carbuncles, boils, and other ailments.

[0027] Turmeric has a pungent and bitter taste and is warm in nature. It has the effects of promoting blood circulation, relieving pain and promoting menstruation. It is used for symptoms such as chest and rib pain, amenorrhea, blood stasis, and rheumatic shoulder and arm pain.

[0028] Terminalia chebula has a bitter, sour, and astringent taste, and is neutral in nature. It has the effects of detoxification and regulating body constitution, and is used for symptoms such as imbalance of the three roots and hematochezia.

[0029] Dried ginger is pungent and hot in nature; it has the effects of dispelling cold and aiding digestion, and is used for symptoms such as cold pain in the stomach and abdomen, vomiting and diarrhea.

[0030] Puffballs are pungent in taste and neutral in nature; they have the effects of clearing the lungs and relieving sore throat, detoxifying and stopping bleeding, and are used for symptoms such as sore throat, cough with loss of voice, hematemesis, and epistaxis.

[0031] Akebia trifoliata has a bitter taste and cold properties; it has the effects of clearing heart fire, promoting diuresis, and regulating menstruation. It is used for edema, irritability and dark urine, mouth and tongue sores, amenorrhea and insufficient lactation.

[0032] Prepared licorice root is sweet in taste and neutral in nature; it has the effects of tonifying the spleen and stomach, replenishing qi, and relieving cough. It is used for symptoms such as spleen and stomach weakness, cough, and asthma.

[0033] Chinese arborvitae (Platycladus orientalis) has a bitter and astringent taste and is cold in nature. It has the effects of cooling the blood and stopping bleeding, resolving phlegm and relieving cough, and is used for hemoptysis, epistaxis, hematuria and other symptoms.

[0034] Piper longum has a pungent taste and is hot in nature; it has the effects of dispelling cold and relieving pain, and is used for symptoms such as cold pain in the stomach and abdomen, vomiting and diarrhea.

[0035] Polygonatum has a sweet taste and neutral properties; it has the effects of strengthening the spleen, moistening the lungs, and benefiting the kidneys. It is used for symptoms such as weakness of the spleen and stomach, fatigue, dry mouth and poor appetite, and deficiency of essence and blood.

[0036] The present invention discloses the following technical effects:

[0037] This invention, based on Mongolian medical theory, statistically analyzes Mongolian medicines used for enemas to treat ulcerative colitis throughout history, and combines this with the pathogenesis of ulcerative colitis to select suitable drugs and scientifically formulate them, thereby developing a Mongolian medicine composition with unique Mongolian medical characteristics for treating ulcerative colitis. Furthermore, based on this Mongolian medicine composition, a Mongolian medicine-specific enema agent for treating ulcerative colitis has been developed. This invention fully demonstrates the unique value and advantages of Mongolian medical theory in modern disease treatment, providing new ideas and methods for the treatment of ulcerative colitis.

[0038] This invention develops a Mongolian medicine-specific enema that combines traditional Mongolian medicine theory with modern pharmaceutical technology, and its formula is designed specifically for the pathological characteristics of ulcerative colitis (UC). Experimental data show that this enema can significantly reduce the colonic inflammation score in model rats and improve the pathological changes in colonic tissue. Furthermore, in clinical trials, patients using this enema showed a higher cure rate and a lower recurrence rate, fully demonstrating its definite efficacy.

[0039] The Mongolian medicine-specific enema developed in this invention has significant technical advantages in the treatment of ulcerative colitis, including improved local drug efficacy, reduced adverse reactions, clear clinical efficacy, and innovative Mongolian medicine features, providing a safe, effective, and economical treatment option for UC patients. Attached Figure Description

[0040] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0041] Figure 1 Statistical graphs showing the gross morphological scores of the colonic mucosa in each group of rats; where ☆ represents a difference compared with the SASP group (P>0.05); ◇ represents a difference compared with the conventional treatment group (P<0.05); ★ represents a difference compared with the normal group (P<0.05); and ※ represents a difference compared with the model control group (P<0.05).

[0042] Figure 2 The images show the results of histopathological examination of the colonic mucosa of rats in each group; where ☆ represents comparison with the SASP group, P>0.05; ◇ represents comparison with the traditional agent group, P<0.05; ★ represents comparison with the normal group, P<0.05; and ※ represents comparison with the model control group, P<0.05.

[0043] Figure 3The staining images show the colon tissues of rats in each group; where A, G, and G represent the normal group, model control group, optimal low-dose group, optimal medium-dose group, optimal high-dose group, conventional group, and mesalazine group, respectively. Detailed Implementation

[0044] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as a limitation of the present invention, but rather as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0045] It should be understood that the terminology used in this invention is merely for describing particular embodiments and is not intended to limit the invention. Furthermore, with respect to numerical ranges in this invention, it should be understood that each intermediate value between the upper and lower limits of the range is also specifically disclosed. Any stated value or intermediate value within a stated range, as well as each smaller range between any other stated value or intermediate value within said range, is also included in this invention. The upper and lower limits of these smaller ranges may be independently included or excluded from the range.

[0046] Unless otherwise stated, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. While only preferred methods and materials have been described herein, any methods and materials similar or equivalent to those described herein may be used in the implementation or testing of this invention. All references to this specification are incorporated by way of citation to disclose and describe methods and / or materials associated with those references. In the event of any conflict with any incorporated reference, the content of this specification shall prevail.

[0047] Various modifications and variations can be made to the specific embodiments described in this specification without departing from the scope or spirit of the invention, as will be apparent to those skilled in the art. Other embodiments derived from this specification will also be readily apparent to those skilled in the art. This specification and embodiments are merely exemplary.

[0048] The terms “include,” “including,” “have,” “contain,” etc., used in this article are all open-ended terms, meaning that they include but are not limited to.

[0049] Example 1

[0050] Ingredients: 30g pomegranate seeds, 20g cinnamon, 20g gypsum, 20g cardamom, 20g forsythia, 20g turmeric, 20g chebula, 20g dried ginger, 20g puffball, 20g akebia stem, 10g prepared licorice root, 10g arborvitae, 10g long pepper, 10g edible alkali, and 10g polygonatum.

[0051] Preparation method of Mongolian medicine-specific enema for treating ulcerative colitis:

[0052] (1) Crush the Mongolian medicine raw materials in the above raw material formula, pass them through a 100-mesh sieve, and obtain the medicinal powder of each Mongolian medicine raw material.

[0053] (2) Mix the powdered medicinal materials evenly according to the above raw material formula to obtain a mixture.

[0054] (3) Take 5g of the mixture, add 100mL of distilled water, boil and cool naturally to room temperature. After separating the insoluble matter, the clear liquid is obtained, which is the Mongolian medicine enema for treating ulcerative colitis.

[0055] Example 2

[0056] Ingredients: 35g pomegranate seeds, 15g cinnamon, 25g gypsum, 25g cardamom, 15g forsythia, 15g turmeric, 25g chebula, 25g dried ginger, 25g puffball, 15g akebia stem, 15g prepared licorice root, 5g arborvitae, 5g long pepper, 5g alkali, and 15g polygonatum.

[0057] Preparation method of Mongolian medicine-specific enema for treating ulcerative colitis:

[0058] (1) Crush the Mongolian medicine raw materials in the above raw material formula, pass them through a 100-mesh sieve, and obtain the medicinal powder of each Mongolian medicine raw material.

[0059] (2) Mix the powdered medicinal materials evenly according to the above raw material formula to obtain a mixture.

[0060] (3) Take 5g of the mixture, add 100mL of distilled water, boil and cool naturally to room temperature. After separating the insoluble matter, the clear liquid is obtained, which is the Mongolian medicine enema for treating ulcerative colitis.

[0061] Example 3

[0062] Ingredients: 25g pomegranate seeds, 25g cinnamon, 15g gypsum, 15g cardamom, 25g forsythia, 25g turmeric, 15g chebula, 15g dried ginger, 15g puffball, 15g akebia stem, 5g prepared licorice root, 15g arborvitae, 15g long pepper, 15g alkali, and 5g polygonatum.

[0063] Preparation method of Mongolian medicine-specific enema for treating ulcerative colitis:

[0064] (1) Crush the Mongolian medicine raw materials in the above raw material formula, pass them through a 100-mesh sieve, and obtain the medicinal powder of each Mongolian medicine raw material.

[0065] (2) Mix the powdered medicinal materials evenly according to the above raw material formula to obtain a mixture.

[0066] (3) Take 5g of the mixture, add 100mL of distilled water, boil and cool naturally to room temperature. After separating the insoluble matter, the clear liquid is obtained, which is the Mongolian medicine enema for treating ulcerative colitis.

[0067] Effect verification example

[0068] 1. Experimental materials

[0069] Experimental animals: SPF - level male SD rats, 6 - 8 weeks old, weighing about 180 - 220 g, purchased from Beijing Sibefu Biotechnology Co., Ltd. with the license number of SCXK(Beijing)2019 - 0010.

[0070] 2. Experimental methods

[0071] 2.1 Preparation of experimental drugs

[0072] Low, medium, and high - dose Mongolian medicine enema: Using the equivalent dose conversion method for humans and animals to calculate the dosing dose for rats, the low dose is 0.675 g / kg, the medium dose is 1.35 g / kg, and the high dose is 2.70 g / kg. According to the raw material formula and preparation method of Example 1, Mongolian medicine enemas with different doses were prepared.

[0073] Mesalazine (SASP): Using the equivalent dose conversion method for humans and animals, the dose of mesalazine is 0.36 g / kg, and it was fully mixed in distilled water for later use.

[0074] Traditional Niruhaji: A traditional formula recorded in the classic Mongolian medicine work "Four Parts of Sweet Dew".

[0075] 2.2 Grouping of experimental animals

[0076] The rats were placed in a laboratory at room temperature of 22°C and relative humidity of 50%, given sufficient feed and drinking water, and adaptively fed for 7 days. During this period, the body weight of the rats increased steadily and there were no obvious differences in their daily behaviors. They were randomly divided into a normal group, a model control group, a low - dose group, a medium - dose group, a high - dose group, a mesalazine group (SASP), and a traditional group, with 12 rats in each group.

[0077] 2.3 Modeling

[0078] After the adaptive feeding period, the rats in each group were fasted for 24 h. For all groups except the normal group, the TNBS / ethanol method was used to establish the model. The method is as follows: A silicone tube with a diameter of 2 mm (one end fixed to a 1 - mL syringe and the other end smeared with liquid paraffin) was inserted into the anus, with an insertion length of about 8 cm. A mixed reagent prepared by mixing 100 mg / kg TNBS + 0.25 mL of 50% absolute ethanol was slowly injected into the intestinal cavity, and then the rats were held upside - down for 3 min. The normal group was fed with distilled water according to their body weight and then conventionally raised.

[0079] Model evaluation:

[0080] After modeling, observe the rats' mental state, eating and defecation, and give them a DAI score. Furthermore, observe the general changes in the rat colon to evaluate whether the modeling was successful.

[0081] 1) General condition: Compared with the normal group, other rats showed reduced daily food and water intake, fluffy fur, poor color, and reduced activity.

[0082] 2) DAI Score: According to the instructions of the Fecal Occult Blood Qualitative Detection Kit (FOB), take an appropriate amount of rat feces with a medical cotton swab. An immediate blue-black color (+) indicates a large amount of occult blood; a blue color appearing within 30-60 seconds after adding the reagent (±) indicates a small amount of occult blood; no color development after 2 minutes (-) indicates no occult blood. Furthermore, record the rat's weight daily.

[0083] 3) General changes in the colon: On the third day of modeling, two rats were randomly selected from the normal group and the model group respectively. The colonic wall was observed with the naked eye, and the presence of ulcers, edema, adhesions or perforations and changes in colon length were carefully observed. The rats in the model group showed symptoms such as ulcers, edema, and shortened colonic length.

[0084] 2.4 Animal administration

[0085] Three days after model establishment and observation, drug enema treatment was initiated. Before the enema, the abdomen, back, and perianal area of ​​the rats were gently massaged to empty the feces. The drug administration details for each group are shown in Table 3.

[0086] Table 3 Experimental Groups

[0087] Group Dosage normal group Enema with distilled water, once daily for 14 consecutive days. Model control group Modeling + enema with distilled water, once daily for 14 consecutive days. Excellent Group Modeling + high-dose Mongolian medicine-specific enema; once daily, for 14 consecutive treatments. Excellent Middle Group Modeling + medium-dose Mongolian medicine-specific enema; once daily, for 14 consecutive treatments. Superior and Low Group Modeling + low-dose Mongolian medicine-specific enema; once daily, for 14 consecutive treatments. Traditional Group Modeling + traditional nitrohazine; once daily for 14 consecutive treatments. SASP Group Modeling + Mesalazine; once daily for 14 consecutive treatments.

[0088] 2.5 Specimen Collection

[0089] After 14 days of drug enema treatment, rats were fasted for 24 hours but allowed free access to water. They were then anesthetized by intraperitoneal injection of 20% urethane at a dose of 1.2 g / kg and euthanized by vertebral dislocation. The abdomen was cut along the midline with surgical scissors, and the colonic tissue between the rectum and cecum was harvested. The tissue was longitudinally cut and the intestinal lumen was cleaned with physiological saline to remove any waste. The tissue was divided into two sections. One section was fixed in paraformaldehyde for HE and IHC staining. The remaining section was placed in sterile, enzyme-free cryovials and immediately transferred to a -80°C freezer.

[0090] 2.6 Indicator Testing

[0091] 2.6.1 Disease Activity Index

[0092] Rats were observed daily for body weight, fecal formation, and the presence of visible blood or occult blood in their stool. Occult blood was detected using a FOB kit on day 3 after model establishment and on days 3, 8, and 14 of intervention. Based on the observation results, the DAI scoring system was used to assess the activity level of UC.

[0093] 2.6.2 Histopathological changes in rat colon tissue

[0094] 1) Tissue fixation, dehydration, and clearing: A portion of the colon was fixed in 10% paraformaldehyde, with the solution changed every 24 hours. A 0.5 cm sample was placed in an embedding cassette and rinsed under running water for 2 hours. The tissue was then dehydrated twice, for 1 hour each in 75% anhydrous ethanol, 85% anhydrous ethanol, 90% anhydrous ethanol, 95% anhydrous ethanol, and 100% anhydrous ethanol, each time for 40 minutes. Xylene was then used twice, for 15 minutes each time, to clear the tissue.

[0095] 2) Paraffin infiltration, embedding, and sectioning: Immerse the colon tube in 60°C liquid paraffin for 1 hour in a biological tissue embedding machine. Place the paraffin-insulated colon tube vertically in the center of the mold, add drops of dissolved liquid paraffin to fill the mold, and place it on a freezing stage for about 3 minutes. Pre-cool the paraffin block in a -20°C freezer for 20 minutes, then fix the frozen paraffin block on a microtome, trim it, and section it to a thickness of 3.5 μm. Carefully transfer the sectioned paraffin to 42°C warm water for spreading. Use an adhesive slide to retrieve the tissue and mark it. Preheat the slide to 60°C for 40 minutes for subsequent staining.

[0096] 3) Staining and mounting: xylene twice for 5 min, 100%, 95%, 85%, and 75% graded alcohols for 5 min each, hematoxylin for 6 min, rinse with running water for 5 sec, differentiation solution for 8 sec, warm water for 6 min to return to blue, eosin for 8 sec, running water for a few seconds, 95% I, 95% II, and 100% graded alcohols for 2 min each, xylene twice for 5 min, mount with neutral resin, and analyze the images under a microscope at 200x magnification.

[0097] 3. Experimental Results

[0098] The results of the detection of gross morphology and histopathological changes of the colonic mucosa in each experimental group are shown below. Figures 1-3 .

[0099] Compared with the normal group of rats, the gross morphological score of the colonic mucosa in the model control group was significantly higher (P<0.05), and the histopathological changes of the colon indicated severe mucosal damage (P<0.05). These results indicate that the rat model of ulcerative colitis was successfully established.

[0100] Compared with the model control group and the traditional group, after treatment with the Mongolian medicine-specific enema agent (medium and high doses) of the present invention, the gross morphology score of the colonic mucosa was significantly reduced (P<0.05), and the pathological histological changes were significantly improved.

[0101] The experimental results above show that the Mongolian medicine-specific enema prepared in this invention can effectively treat ulcerative colitis.

[0102] The embodiments described above are merely preferred embodiments of the present invention and are not intended to limit the scope of the present invention. Various modifications and improvements made by those skilled in the art to the technical solutions of the present invention without departing from the spirit of the present invention should fall within the protection scope defined by the claims of the present invention.

Claims

1. A Mongolian medicine composition for treating ulcerative colitis, characterized in that, The Mongolian medicine composition comprises the following components in parts by weight: 25-35 parts pomegranate seeds, 15-25 parts cinnamon, 15-25 parts gypsum, 15-25 parts cardamom, 15-25 parts forsythia, 15-25 parts turmeric, 15-25 parts chebula, 15-25 parts dried ginger, 15-25 parts puffball, 15-25 parts akebia stem, 5-15 parts prepared licorice root, 5-15 parts oriental arborvitae, 5-15 parts long pepper, 5-15 parts alkali, and 5-15 parts polygonatum. The alkali mentioned is edible alkali.

2. The Mongolian medicine composition according to claim 1, characterized in that, The Mongolian medicine composition consists of the following components in parts by weight: 30 parts pomegranate seeds, 20 parts cinnamon, 20 parts gypsum, 20 parts cardamom, 20 parts forsythia, 20 parts turmeric, 20 parts chebula, 20 parts dried ginger, 20 parts puffball, 20 parts akebia stem, 10 parts prepared licorice root, 10 parts arborvitae, 10 parts long pepper, 10 parts alkali, and 10 parts polygonatum.

3. The use of the Mongolian medicine composition as described in claim 1 or 2 in the preparation of a medicament for treating ulcerative colitis.

4. The application according to claim 3, characterized in that, The drug is in the form of powder or enema.

5. A drug for treating ulcerative colitis, characterized in that, The raw materials include the Mongolian medicine composition as described in claim 1 or 2.

6. The drug according to claim 5, characterized in that, The drug also includes pharmaceutically acceptable excipients.

7. The drug according to claim 6, characterized in that, The drug is in powder form.

8. The drug according to claim 6, characterized in that, The drug is an enema.

9. A method for preparing the drug as described in claim 7, characterized in that, The process includes the step of mixing the powdered medicinal materials in the prescribed amounts evenly to obtain the drug.

10. A method for preparing the drug as described in claim 8, characterized in that, Includes the following steps; Mix the powdered medicinal materials in the prescribed amounts until homogeneous to obtain a mixture; The mixture is added to distilled water and boiled. After cooling, the insoluble matter is separated and removed to obtain a clear liquid, which is the drug.

Images